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Abstract
Background: To study the efficacy and safety of cilostazol on ischemic stroke prevention and treatment, systematic
reviews of related clinical randomized controlled trials were analyzed.
Methods: We searched the main databases for eligible trials including literature from January 1966 to November
2012 in MEDLINE, reports from 1980 to November 2012 in EMBASE, and all the studies published in EBSCO,
Springer, Ovid, and Cochrane library citations. We also searched for keywords, including cilostazol and aspirin.
RewMan 5.0 software was used to conduct the meta-analysis.
Results: Our search yielded five eligible trials. The effects of cilostazol and aspirin on ischemic stroke prevention
and treatment were almost equal (combined odds ratio (OR) 0.78, 95% confidence interval (CI) (0.59, 1.04)).
Additionally, both magnetic resonance angiography (MRA) and transcranial Doppler (TCD) examination showed that
cilostazol could significantly decrease the incidence of intracranial artery stenosis exacerbation (MRA: combined OR
0.22, 95% CI (0.07, 0.68); TCD: combined OR 0.17, 95% CI (0.05, 0.51)). In terms of adverse reactions, there were
slightly fewer incidences of major bleeding with cilostazol than with aspirin (combined OR 0.38, 95% CI (0.24, 0.60)),
and there was no difference in the number of heart palpitations between cilostazol and aspirin. However, the
incidence of gastrointestinal disorders, dizziness, and headaches caused by cilostazol was greater.
Conclusions: Cilostazol might be a more effective and safer alternative to aspirin for patients with ischemic stroke.
Further studies are required to confirm whether cilostazol is a suitable therapeutic option for secondary stroke
prevention in larger cohorts of patients with ischemic stroke.
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Background
Ischemic stroke, which indicated that ischemia is caused
by blockage, is a major cause of death and disability
worldwide, and contributes significant financial burdens
[1]. Owing to this severe cost of ischemic stroke, sec-
ondary prevention, namely preclinical prevention, plays
an important role in reducing mortality and morbidity
[2]. Antiplatelet treatment is a mainstay in acute and
long-term secondary stroke prevention [3]. The most
widely used antiplatelet drug for stroke prevention is as-
pirin, which significantly reduces the recurrence rate of
ischemic stroke [4]. However, the clinical application of
aspirin is limited due to major hemorrhagic adverse ef-
fects. Although several studies concluded that the
advantages of aspirin are enough to outweigh the risk of
hemorrhagic infarctions in most populations [5], the po-
tential of adverse effects for the application of aspirin
still cannot be ignored, particularly for individuals in
Asia [6]. Moreover, many studies also found that despite
regular antiplatelet treatment, some patients experienced
thromboembolic events [7-9]. Those patients are clinic-
ally designated as aspirin resistant or non-responders.
The incidence of low response or non-response to as-
pirin ranges between 5% and 60% [9]. Therefore, search-
ing for antiplatelet agents with minimum complications
and drug resistant is important.
Cilostazol has been shown to be an alternative to as-
pirin for secondary prevention in patients with non-
cardioembolic ischemic stroke [10]. Cilostazol is a selective
phosphodiesterase 3 (PDE3) inhibitor, possessing a poten-
tially powerful means to produce various pleiotropic effects.
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Currently, promoting evidence shows that cilostazol can
serve as an antiplatelet agent. The effects of cilostazol on
stroke prevention are caused by its protective effect against
secondary cerebral infarctions [11]. Although cilostazol is
widely used for the treatment of intermittent claudication
with peripheral artery occlusion and for the prevention of
ischemic stroke [12], reported clinical outcomes on its effi-
cacy and side effects are conflicting, and systemic reviews
are needed. In our paper, we assess the safety and efficacy
of cilostazol versus aspirin for secondary stroke prevention
in current clinical randomized controlled trials, aiming to




We fully researched MEDLINE, EMBASE, EBSCO,
Springer, Ovid, and Cochrane library citations.
1) MEDLINE: January 1966 to November 2012,
including established searches using a Cochrane
Randomized Controlled Trials filter to identify
randomized controlled trials combined with terms
that will include cilostazol and aspirin.
2) EMBASE: 1980 to November 2012.
3) The Cochrane Central Register of Controlled Trials.
4) All reference lists of identified studies in EBSCO,
Springer, Ovid, and Cochrane library citations.
Inclusion criteria
The published studies should be randomized controlled
trials (RCTs), in which the patients were randomly
grouped and accepted different interventions for com-
parison. All patients in the studies should have a medical
history of ischemic stroke or transient ischemic attack
and meet WHO criteria [13]. Patients should be older
than 18 years. Therapeutic effects studied should include
the incidence of ischemic stroke, the state of exacerba-
tion of intracranial artery stenosis, and changes to the
intima-media thickness. The following side effects
should be noted: major bleeding, including intracranial
hemorrhage and massive hemorrhage needing hospital
blood transfusion, palpitation, gastrointestinal disorders
(diarrhea, constipation, and so on), headaches, and
dizziness.
Exclusion criteria are non-RCTs, patients with a his-
tory of gastrointestinal bleeding, bloody urine, conjunc-
tival hemorrhageor patients with serious diseases, such
as malignant neoplasm, heart failure, or renal failure.
Quality assessment and data extraction
Quality assessment included the adequacy of the random
allocation method, the hidden nature of the random al-
location method, the adoption of blinding methods, and
evaluation of withdrawals.
Extracted data included: (1) general information: such
as the topic of research, authors, the sources of
Figure 1 Forest plots of comparison of the incidence of ischemic stroke between cilostazol and aspirin groups in prevention and cure
of ischemic stroke. Heterogeneity test, chi-square statistic with degrees of freedom and P value; inconsistency among results, I2 test for overall
effect, Z statistic with P. CI, confidence interval; df, degrees of freedom; M-H, Mantel-Haenszel method.
Figure 2 Forest plots of comparison of the progression of intracranial artery stenosis (by magnetic resonance angiography) between
cilostazol and aspirin groups in prevention and cure of ischemic stroke. Heterogeneity test, chi-square statistic with degrees of freedom
and P value; inconsistency among results, I2 test for overall effect, Z statistic with P value. CI, confidence interval; df, degrees of freedom; M-H,
Mantel-Haenszel method.
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literatures and so on; (2) research characteristics: design
scheme, research strategies, implementation methods,
measures to prevent bias, main test results and so on;
(3) outcome measures: such as follow-up time, treatment
of data from patients lost to follow-up or withdrawing
from the study, curative effects and side effects, collec-
tion of headcounts of each group and the number of
various events.
Statistical analysis
Meta-analysis was carried out by RevMan 5.0 provided
by the Cochrane Collaboration. Odds ratios (OR) were
used to determine effect size, along with 95% confidence
interval (CI). Heterogeneity in results across studies was
examined using the chi-square or tau- squaretest. When
heterogeneity was not observed (P > 0.01,I2 ≤ 56%), the
effect size was calculated based on a fixed-effects model;
otherwise a random-effects model was used. The overall
effect estimate was analyzed by Mantel-Haenszel




Using this retrieval method, five eligible trials published be-
tween 2005 and 2011 were found [14-18], containing 4,052
cases of patients from different countries including Japan,
Korea, and China. Among the five eligible trials, four com-
pared the efficacy of cilostazol and aspirin [14-17], and one
compared cilostazol and a placebo based on aspirin usage
[18]. With respect to main curative effects, four analyzed
the incidence of ischemic stroke [14-17], and two analyzed
exacerbation of intracranial artery stenosis [16,18], but no
RCTs referred to intima-media thickness in carotid arteries
of stroke patients. Regarding side effects, four analyzed
major bleeding, dizziness and headaches [14-17], three ana-
lyzed palpitation [14,15,17], and three analyzed gastrointes-
tinal disorders [14-16]. All five trials applied a random and
double-blind method, but only one used allocation conceal-
ment [15].
Efficacy analysis
Incidence of ischemic stroke
Four trials [14-17] compared the incidence of ischemic
stroke in cilostazol groups and aspirin groups. A fixed-
effects model was chosen, because of the poor heterogen-
eity (P = 0.77, I2 = 0%). The combined OR was 0.78 and
95% CI (0.59, 1.04), with no statistical significance (Z = 1.68,
P = 0.09). Therefore, no difference was observed between
cilostazol and aspirin groups in prevention and cure of is-
chemic stroke (see Figure 1).
Progression of intracranial artery stenosis
Two studies [16,18] focused on the progression of intracra-
nial artery stenosis, with placebo and aspirin as the control,
respectively. Magnetic resonance angiography (MRA) and
transcranial Doppler (TCD) were applied in both studies to
examine arteriostenosis. There was no heterogeneity in the
results of MRA examination among studies (P = 0.25,
I2 = 23%), and a fixed-effects model was adopted. The
Figure 3 Forest plots of the comparison of the exacerbation of intracranial artery stenosis (by transcranial Doppler) between cilostazol
and aspirin group. Heterogeneity test, chi-square statistic with degrees of freedom and P value; inconsistency among results, I2 test for overall
effect, Z statistic with P value. CI, confidence interval; df, degrees of freedom; M-H, Mantel-Haenszel method.
Figure 4 Forest plots of the comparison of major bleeding between cilostazol and aspirin group. Heterogeneity test, chi-squarestatistic
with degrees of freedom and P value; inconsistency among results, I2 test for overall effect, Z statistic with P value. CI, confidence interval; df,
degrees of freedom; M-H, Mantel-Haenszel method.
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combined OR was 0.22 with 95% CI (0.07, 0.68), with statis-
tical significance (Z = 2.63, P = 0.009). Therefore, according
to MRA examination, cilostazol was more effective than as-
pirin in preventing intracranial artery stenosis progression
(see Figure 2).
No heterogeneity was observed in results of TCD
examination among studies (P = 0.16, I2 = 50%), and a
fixed-effects model was applied. The combined OR was
0.17 with 95% CI (0.05, 0.51), with statistical significance
(Z = 3.12, P = 0.002). Therefore, according to TCD exam-
ination, cilostazol was superior to the control in preven-
tion and treatment of intracranial artery stenosis
progression (see Figure 3).
Adverse effects analysis
Major bleeding
Four eligible studies [14-17] compared the incidence of
major bleeding in cilostazol and aspirin groups. Since no
heterogeneity was observed (P = 0.93, I2 = 0%), a fixed-
effects model was chosen. The combined OR was 0.38
and 95% CI (0.24, 0.60), with statistical significance
(Z = 4.15, P < 0.0001). Thus, the incidence of major
bleeding was slightly reduced with cilostazol, compared
with aspirin (see Figure 4).
Palpitation
Three trials [14,15,17] compared the incidence of palpi-
tation in cilostazol and aspirin groups. A random-effects
model was used for the heterogeneity (P < 0.01,
I2 = 94%). The combined OR was 0.96 with 95% CI
(0.15, 6.21), with no statistical significance (Z = 0.04,
P = 0.97). So there was no difference in the side effect
of heart palpitations between cilostazol and aspirin
(see Figure 5).
Gastrointestinal disorders
Three trials [14-16] compared the incidence of gastro-
intestinal disorders in cilostazol and aspirin groups. A
fixed-effects model was used for the poor heterogeneity
(P = 0.61, I2 = 0%). The combined OR was 1.23 with 95%
CI (1.04, 1.46), with statistical significance (Z = 2.40,
P = 0.02) (see Figure 6). Thus, the incidence of gastro-
intestinal disorders caused by cilostazol was higher than
the incidence of gastrointestinal disorders caused by
aspirin.
Dizziness
Four studies [14-17] compared the incidence of dizziness
in cilostazol and aspirin groups. Fixed-effects model was
used for the poor heterogeneity (P = 0.58, I2 = 0%). The
combined OR was 1.44 with 95% CI (1.15, 1.80), with
statistical significance (Z = 3.18, P = 0.001). Therefore,
there was more dizziness associated with cilostazol than
with aspirin (see Figure 7).
Headache
Four studies [14-17] compared the incidence of headache
in cilostazol and aspirin groups. A fixed-effects model was
used for the poor heterogeneity (P = 0.09, I2 = 55%). The
combined OR was 1.78 with 95% CI (1.52, 2.10), with
Figure 5 Forest plots of the comparison of palpitation between cilostazol and aspirin group. Heterogeneity test, chi-squared statistic with
degrees of freedom and P value; inconsistency among results, I2 test for overall effect, Z statistic with P value. CI, confidence interval; df: degrees
of freedom, M-H, Mantel-Haenszel method.
Figure 6 Forest plots of the comparison of gastrointestinal disorders between cilostazol and aspirin group. Heterogeneity test, chi-
squarestatistic with degrees of freedom and P value; inconsistency among results, I2 test for overall effect, Z statistic with P value. CI, confidence
interval; df, degrees of freedom; M-H, Mantel-Haenszel method.
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statistical significance (Z = 6.97, P < 0.00001). Therefore, the
prevalence of headaches with cilostazol was higher than
that with aspirin (see Figure 8).
Discussion
Several antiplatelet agents, as suitable options for the
secondary prevention drugs of ischemic stroke, are cur-
rently recommended by the American Heart Association
and the American Stroke Association [19], such as as-
pirin, cilostazol, and clopidogrel [20,21].
Among these antiplatelet agents, aspirin is often pre-
scribed as a mainstay agent for secondary stroke preven-
tion because therapeutic monitoring is not required, it
achieves a significant reduction in the absolute risk of
acute ischemic and it is significantly lower in cost than
all other antiplatelet agents [22]. Although aspirin has
these advantages for secondary stroke prevention, in
pooled analyses, it is reported [23] that its use is also as-
sociated with dosage-related gastrointestinal and intra-
cranial hemorrhages. A significantly increase in the
absolute risk of hemorrhagic stroke (+12 per 10,000 per-
sons) has been reported, which translated to a relative
risk increase of 84% with aspirin therapy [5]).
Recent clinical trial evidence suggests that cilostazol, a
selective PDE3 inhibitor, may be a safer and more effect-
ive alternative than aspirin for secondary stroke preven-
tion in Asian patients. Cilostazol’s utility is approved as
a medication for ischemic stroke prevention by the Food
and Drug Administration because it exerts antiplatelet
and antithrombotic effects [24]. Studies reported that
cilostazol reversibly inhibits the activation of PDE-3A,
which is mainly distributed in platelets, heart muscle,
and vascular smooth muscle. Cilostazol blocks platelet
adenosine uptake and adenosine-induced platelet activa-
tion, to prevent platelet aggregation [25]. In vitro
and in vivo data further demonstrate that cilostazol in-
duces the expression of prostacyclin, which is the
endothelium-derived antiplatelet compound, while as-
pirin allows for platelet aggregation through inhibition
of COX and prostacyclin formation [26,27].
In contrast with aspirin for stroke prevention, which
mainly has an antiplatelet effect, cilostazol also exerts
vasodilatory effect and increases human carotid, cere-
bral, coronary, and dermal blood flow [27,28]. Emerging
evidence suggests that cilostazol inhibits the PDE-3 en-
zyme in human smooth muscle cells, leading to effects
on vasculature. These effects include inhibition of hu-
man smooth muscle proliferation by growth factors, re-
version of intracranial atherosclerotic lesions, and
improvements in cerebral blood flow [18,29]. Addition-
ally, cilostazol increases levels of vascular endothelial
growth factor, which serves to repair damaged vascular
epithelium [27]. In our analysis, we collectively found a
trend for the improvement of the efficacy of cilostazol
over aspirin. Moreover, the combined properties of anti-
platelet, antithrombotic, and effects on vasculature
Figure 7 Forest plots of the comparison of the incidence of dizziness between cilostazol and aspirin group. Heterogeneity test, chi-
squarestatistic with degrees of freedom and P value; inconsistency among results, I2 test for overall effect, Z statistic with P value.CI, confidence
interval; df, degrees of freedom; M-H, Mantel-Haenszel method.
Figure 8 Forest plots of the comparison of the Incidence of headache between cilostazol and aspirin group. Heterogeneity test, chi-
squarestatistic with degrees of freedom and P value; inconsistency among results, I2 test for overall effect, Z statistic with P value. CI, confidence
interval; df, degrees of freedom; M-H, Mantel-Haenszel method.
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favorably contribute to the utility of cilostazol for stroke
prevention [30].
Intracranial arterial stenosis is one of the most common
causes of stroke worldwide and is associated with a high
risk of recurrent stroke. Therefore, its prevention can re-
duce the risk of ischemic stroke. A randomized study of
135 patients with symptomatic intracranial arterial stenosis
showed that treatment with cilostazol significantly reduced
progression of the stenosis [31]. Moreover, cilostazol also
significantly prevented progression of carotid artery intima-
media thickness [32], which is an indicator of atheroscler-
osis and an established risk factor for stroke [33,34]. In our
study, we found that cilostazol can significantly prevent
progression of intracranial artery stenosis aggravation, as
determined using MRA and TCD (MRA: combined
OR 0.22, 95% CI (0.07, 0.68); TCD: combined OR 0.17,
95% CI (0.05, 0.51)).
It is well known that major bleeding is a main side ef-
fect of antiplatelet drugs, including aspirin. Some re-
ported papers hint that there is evidence of fewer
incidences of bleeding with cilostazol than with clopido-
grel or aspirin [35], and our study confirmed those re-
sults (combined OR 0.38, 95% CI (0.24,0.60)). With
respect to palpitation, the effect with cilostazol is almost
as the same as that with aspirin, but cilostazol is associ-
ated with more minor adverse effects, such as gastro-
intestinal disorders (combined 1.23, 95% CI (1.04, 1.46)),
dizziness (combined OR 1.44, 95% CI (1.15, 1.80)) and
headaches (combined OR 1.78, 95% CI (1.52, 2.10)).
Conclusion
Our meta-analysis of five RCTs investigated the safety
and efficacy outcomes in ischemic stroke patients
treated with cilostazol. The results showed that cilosta-
zol might be a more effective and safer alternative to as-
pirin for patients with ischemic stroke. However, the
number of surveys in the literature was limited and there
might be a publication bias on application and interpret-
ation. Additionally, recruited papers introduced little on
allocation concealment, which is an important measure
to ensure the quality of RCTs. Besides, there are few
RCT studies focused on the effect of cilostazol on intra-
cranial arterial stenosis and increased intima-media
thicknessin patients with ischemic stroke. Further trials
should examine the safety and efficacy of cilostazol in
larger cohorts of patients and in comparison with other
drugs currently used in secondary stroke prevention.
Abbreviations
CI: Confidence interval; df: Degrees of freedom; MRA: Magnetic resonance
angiography; OR: Odds ratio; PDE3: Phosphodiesterase 3; RCT: Randomized
controlled trial; TCD: Transcranial Doppler.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YNQ and QB conceived of the study, participated in its design and
coordination, draft the manuscript participated in performed the statistical
analysis. Both authors read and approved the final manuscript.
Received: 25 September 2013 Accepted: 12 November 2013
Published: 6 December 2013
References
1. Henon H, Godefroy O, Leys D, Mounier-Vehier F, Lucas C, Rondepierre P,
Duhamel A, Pruvo J: Early predictors of death and disability after acute
cerebral ischemic event. Stroke 1995, 26:392–398.
2. Harms H, Prass K, Meisel C, Klehmet J, Rogge W, Drenckhahn C, Göhler J,
Bereswill S, Göbel U, Wernecke KD: Preventive antibacterial therapy in
acute ischemic stroke: a randomized controlled trial. PloS One 2008,
3:e2158.
3. Antiplatelet Trialists’ Collaboration: Collaborative overview of randomised
trials of antiplatelet therapy.I: prevention of death, myocardial infarction,
and stroke by prolonged antiplatelet therapy in various categories of
patients. BMJ 1994, 308:81–106.
4. Rother J, Alberts MJ, Touze E, Mas JL, Hill MD, Michel P, Bhatt DL, Aichner
FT, Goto S, Matsumoto M, Ohman EM, Okada Y, Uchiyama S, D’Agostino R,
Hirsch AT, Wilson PW, Steg PG: Risk factor profile and management of
cerebrovascular patients in the REACH Registry. Cerebrovasc Dis 2008,
25:366–374.
5. He J, Whelton PK, Vu B, Klag MJ: Aspirin and risk of hemorrhagic stroke: a
meta-analysis of randomized controlled trials. JAMA 1998, 280:1930–1935.
6. Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Arima H, Tanaka K, Nakamura H,
Okubo K, Iida M: Trends in the incidence, mortality, and survival rate of
cardiovascular disease in a Japanese community: the Hisayama study.
Stroke 2003, 34:2349–2354.
7. Levine S, Brey R, Joseph C, Havstad S: Risk of recurrent thromboembolic
events in patients with focal cerebral ischemia and antiphospholipid
antibodies. The antiphospholipid antibodies in stroke study group.
Stroke 1992, 23:I29.
8. Bath PM, Iddenden R, Bath FJ: Low-molecular-weight heparins and
heparinoids in acute ischemic stroke a meta-analysis of randomized con-
trolled trials. Stroke 2000, 31:1770–1778.
9. Mijajlovic MD, Shulga O, Bloch S, Covickovic-Sternic N, Aleksic V, Bornstein
NM: Clinical consequences of aspirin and clopidogrel resistance: an
overview. Acta Neurologica Scandinavica 2013, 128:213–219.
10. Kamal AK, Naqvi I, Husain MR, Khealani BA: Cilostazol versus aspirin for
secondary prevention of vascular events after stroke of arterial origin.
Cochrane Database Syst Rev 2011, 1:CD008076.
11. Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Shinohara Y,
Itoh E, Matsuda T, Sawada T: Cilostazol stroke prevention study: a
placebo-controlled double-blind trial for secondary prevention of cere-
bral infarction. J Stroke Cerebrovasc Dis 2000, 9:147–157.
12. Patel DS, Anand IS, Bhatt PA: Evaluation of antidepressant and anxiolytic
activity of phosphodiesterase 3 inhibitor - cilostazol. Indian J Psychol Med
2012, 34:124–128.
13. Hatano S: Experience from a multicentre stroke register: a preliminary
report. Bull World Health Organ 1976, 54:541–553.
14. Lee YS, Bae HJ, Kang DW, Lee SH, Yu K, Park JM, Cho YJ, Hong KS, Kim DE,
Kwon SU, Lee KB, Rha JH, Koo J, Han MG, Lee SJ, Lee JH, Jung SW, Lee BC,
Kim JS: Cilostazol in acute ischemic stroke treatment (CAIST trial): a
randomized double-blind non-inferiority trial. Cerebrovasc Dis 2011,
32:65–71.
15. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K,
Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kitagawa Y, Kusuoka H,
Nishimaru K, Tsushima M, Koretsune Y, Sawada T, Hamada C: Cilostazol for
prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-
blind, randomised non-inferiority trial. Lancet Neurol 2010, 9:959–968.
16. Guo JJ, Xu E, Lin QY, Zeng GL, Xie HF: Effect of cilostazol on cerebral
arteries in secondary prevention of ischemic stroke. Neurosci Bull 2009,
25:383–390.
17. Huang Y, Cheng Y, Wu J, Li Y, Xu E, Hong Z, Li Z, Zhang W, Ding M, Gao X,
Fan D, Zeng J, Wong K, Lu C, Xiao J, Yao C: Cilostazol as an alternative to
aspirin after ischaemic stroke: a randomised, double-blind, pilot study.
Lancet Neurol 2008, 7:494–499.
Qian and Bi European Journal of Medical Research 2013, 18:53 Page 6 of 7
http://www.eurjmedres.com/content/18/1/53
18. Kwon SU, Cho YJ, Koo JS, Bae HJ, Lee YS, Hong KS, Lee JH, Kim JS:
Cilostazol prevents the progression of the symptomatic intracranial
arterial stenosis: the multicenter double-blind placebo-controlled trial of
cilostazol in symptomatic intracranial arterial stenosis. Stroke 2005,
36:782–786.
19. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, Halperin JL,
Johnston SC, Katzan I, Kernan WN, Mitchell PH, Ovbiagele B, Palesch YY,
Sacco RL, Schwamm LH, Wassertheil-Smoller S, Turan TN, Wentworth D:
Guidelines for the prevention of stroke in patients with stroke or transi-
ent ischemic attack: a guideline for healthcare professionals from the
American Heart Association/American Stroke Association. Stroke 2011,
42:227–276.
20. Urbano LA, Bogousslavsky J: Antiplatelet drugs in ischemic stroke
prevention: from monotherapy to combined treatment. Cerebrovasc Dis
2004, 17(Suppl 1):74–80.
21. Symeonidis A, Kouraklis-Symeonidis A, Seimeni U, Galani A, Giannakoulas N,
Fragopanagou E, Tiniakou M, Matsouka P, Zoumbos N: Ticlopidine-induced
aplastic anemia: two new case reports, review, and meta-analysis of 55
additional cases. Am J Hematol 2002, 71:24–32.
22. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E,
Roberts RS, Sicurella J, Turpie AG: The Canadian American Ticlopidine
Study (CATS) in thromboembolic stroke. Design, organization, and
baseline results. Stroke 1988, 19:1203–1210.
23. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Baggish JS, Bhatt DL,
Topol EJ: Analysis of risk of bleeding complications after different doses
of aspirin in 192,036 patients enrolled in 31 randomized controlled trials.
Am J Cardiol 2005, 95:1218–1222.
24. Ansara AJ, Shiltz DL, Slavens JB: Use of cilostazol for secondary stroke
prevention: an old dog with new tricks? Ann Pharmacother 2012,
46:394–402.
25. Ikeda Y: Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor.
Thromb Haemost 1999, 82:435–438.
26. Goto S: Cilostazol: potential mechanism of action for antithrombotic
effects accompanied by a low rate of bleeding. Atherosclerosis Suppl 2005,
6:3–11.
27. Liu Y, Shakur Y, Yoshitake M, Kambayashi Ji J: Cilostazol (pletal): a dual
inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine
uptake. Cardiovasc Drug Rev 2001, 19:369–386.
28. Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, Czerwiec F: Cilostazol as
a unique antithrombotic agent. Curr Pharm Des 2003, 9:2289–2302.
29. Kai Y, Watanabe M, Morioka M, Hirano T, Yano S, Ohmori Y, Kawano T,
Hamada J, Kuratsu J: Cilostazol improves symptomatic intracranial artery
stenosis - evaluation of cerebral blood flow with single photon emission
computed tomography. Surg Neurol International 2011, 2:8.
30. Lugnier C: Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new
target for the development of specific therapeutic agents.
Pharmacol Ther 2006, 109:366–398.
31. Sallustio F, Rotondo F, Di Legge S, Stanzione P: Cilostazol in the
management of atherosclerosis. Curr Vasc Pharmacol 2010, 8:363–372.
32. Shinoda-Tagawa T, Yamasaki Y, Yoshida S, Kajimoto Y, Tsujino T, Hakui N,
Matsumoto M, Hori M: A phosphodiesterase inhibitor, cilostazol, prevents
the onset of silent brain infarction in Japanese subjects with Type II
diabetes. Diabetologia 2002, 45:188–194.
33. Touboul PJ, Elbaz A, Koller C, Lucas C, Adrai V, Chedru F, Amarenco P:
Common carotid artery intima-media thickness and brain infarction: the
Etude du Profil Genetique de l’Infarctus Cerebral (GENIC) case–control
study. The GENIC Investigators. Circulation 2000, 102:313–318.
34. Hollander M, Hak AE, Koudstaal PJ, Bots ML, Grobbee DE, Hofman A,
Witteman JC, Breteler MM: Comparison between measures of
atherosclerosis and risk of stroke: the Rotterdam study. Stroke 2003,
34:2367–2372.
35. Wilhite DB, Comerota AJ, Schmieder FA, Throm RC, Gaughan JP, Rao AK:
Managing PAD with multiple platelet inhibitors: the effect of
combination therapy on bleeding time. J Vasc Surg 2003, 38:710–713.
doi:10.1186/2047-783X-18-53
Cite this article as: Qian and Bi: Systematic study of cilostazol on
secondary stroke prevention: a meta-analysis. European Journal of Medical
Research 2013 18:53.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Qian and Bi European Journal of Medical Research 2013, 18:53 Page 7 of 7
http://www.eurjmedres.com/content/18/1/53
